Top Markets
#1 MowCat MowCat +48.88%
#2 Bermuda Shorts Bermuda Shorts +25.32%
#3 Velvet Velvet +25.02%
#4 Biconomy Biconomy +24.70%
#5 Audiera Audiera +24.55%
#6 aPriori aPriori +21.94%
#7 Quack AI Quack AI +20.17%
#8 Derive Derive +18.67%
#9 SkyAI SkyAI +13.30%
#10 Geodnet Geodnet +11.28%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd.

CLGN
Rank in Stocks #35204
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine... CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Share Price
$0.3299
Last synced: 2026-08-14
Market Cap
$4.28M
Change (1 day)
3.55%
Change (1 year)
-87.06%
Country
IL
Trade CollPlant Biotechnologies Ltd. (CLGN)

Category

Healthcare
P/E ratio for CollPlant Biotechnologies Ltd. (CLGN)
P/E ratio as of 2026 TTM: 0
According to CollPlant Biotechnologies Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for CollPlant Biotechnologies Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.